Verona Pharma (VRNA) FDA Announcement summary

Introduction and purpose

• FDA approved Ohtuvayre (ensifentrine) for maintenance treatment of COPD in adults, marking the first inhaled product with a novel dual PDE3/PDE4 inhibition mechanism for COPD in over 20 years.

• Ohtuvayre combines bronchodilation and nonsteroidal anti-inflammatory effects, addressing unmet needs in a large patient population.

Details of approval or decision

• Ohtuvayre is indicated for maintenance treatment of COPD in adults, with no restrictions based on background medication, COPD etiology, or blood eosinophil levels.

• The FDA-approved label highlights its novel dual PDE3/PDE4 inhibition mechanism, differentiating it from other COPD therapies.

• Approval is based on extensive Phase 3 ENHANCE trials, showing clinical benefits as monotherapy and with other maintenance therapies.

• Ohtuvayre is delivered via standard jet nebulizer, not requiring high inspiratory flow or complex coordination.

• No post-marketing requirements or commitments were imposed.

Impact on industry and stakeholders

• Approximately 8.6 million COPD patients in the US are on maintenance therapy, with up to 4.3 million symptomatic and eligible for Ohtuvayre.

• High physician intent to prescribe and strong patient interest in a steroid-free, novel therapy.

• The $2,950/month WAC price reflects value, with each 1% market share equating to ~$1.1 billion in net revenue.

• Broad access initiatives include a comprehensive pharmacy network and support program covering 98% of U.S. patient lives.

• Commercial infrastructure and field personnel are in place for rapid launch.